PD-1/PD-L1 has been translated to the clinical practice, and ICI treatment targeting PD-1/PD-L1 proved to offer significant clinical benefits in many cancers, with an ORR from 20% to 50% in multiple clinical trials and for various types of cancer (5). The gene discussed is CD274; the disease is cancer.